John F. Carey - 28 Mar 2022 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role
VP of Operations
Signature
By: /s/ Stephen Gordon, Attorney-in-Fact
Issuer symbol
TMDX
Transactions as of
28 Mar 2022
Net transactions value
-$63,718
Form type
4
Filing time
30 Mar 2022, 19:19:43 UTC
Previous filing
24 Feb 2022
Next filing
04 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Options Exercise $45,402 +2,813 +256% $16.14* 3,912 28 Mar 2022 Direct F1, F3
transaction TMDX Common Stock Options Exercise $3,381 +1,530 +48% $2.21* 4,722 28 Mar 2022 Direct F1, F3
transaction TMDX Common Stock Options Exercise $43.96 +157 +3.3% $0.2800* 4,879 28 Mar 2022 Direct F1, F3
transaction TMDX Common Stock Sale $112,545 -4,500 -92% $25.01 379 28 Mar 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -2,813 -26% $0.000000 8,125 28 Mar 2022 Common Stock 2,813 $16.14 Direct F1, F4
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -1,530 -12% $0.000000 10,743 28 Mar 2022 Common Stock 1,530 $2.21 Direct F1, F5
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -157 -0.56% $0.000000 27,989 28 Mar 2022 Common Stock 157 $0.2800 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $25.00 to $25.05, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The amount of securities directly owned by the Reporting Person includes 379 shares of common stock acquired under the TransMedics Group, Inc. 2019 Employee Stock Purchase Plan.
F4 The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020.
F5 The option is fully vested.